At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients.
Our scientists are rigorously advancing research and development programs targeting the KRASG12C and KRASG12D mutations.
We are exploring new ways of targeting the protective nest of cells, tissues and blood vessels that make up the tumor microenvironment.
Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers
Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates